Information
for you...
Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
If you live in the U.S., it takes 4-6 weeks to get your screening results. Outside the U.S. it takes a little longer to allow for shipping. In the meantime, here’s some information to look over.
TrialNet forwards all samples from screenings and studies to specialized laboratories across the U.S. This way, all samples are processed in a consistent way, meeting strict requirements for scientific research. The process takes a little longer, but it’s an important step in ensuring you receive the most accurate results.
Please follow along below to see where you may be on TrialNet’s Pathway to Prevention.
If your test results are negative, it means no diabetes-related autoantibodies are present at this time. You are currently at lower risk than someone who tests positive. This is not a guarantee you will never develop T1D, because your autoantibody status can change. Participants younger than 18 years old who are negative for all autoantibodies, may be offered rescreening opportunities.
IMPORTANT: The younger you are, the faster the disease can progress. Symptoms of T1D can come on quickly and be life-threatening. If you or someone you know has symptoms of T1D, be sure to see a healthcare professional right away.
If you test positive for one autoantibody, you will be offered annual retesting for the development of additional autoantibodies.
If you test positive for two or more autoantibodies, you are in the early stages of type 1 diabetes. Your next step is to come in for further testing. An Oral Glucose Tolerance Test (OGTT) will show if you have abnormal blood sugar levels. The test results will tell us whether you qualify for a prevention study or monitoring.
Antibodies are proteins made by the body to protect it from “foreign” substances, such as bacteria or viruses. They are important to our survival. Sometimes antibodies are misdirected and mistakenly attack normal cells. These are called autoantibodies. People develop type 1 diabetes when their bodies make autoantibodies that destroy the body's insulin-making beta cells.
TrialNet looks for up to five autoantibodies that signal an increased risk for T1D:
There may be other autoantibodies yet to be discovered. Your participation in TrialNet research will help us discover more about T1D and how to prevent it.